Trial abstract · §3
TA1-HBV-1 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Sustained virological response in chronic hepatitis B | A modest effect relative to interferon comparators; approved for this indication in several jurisdictions | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Thymosin alpha-1 from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site erythema | — | — | The most commonly reported effect |
| Transient lymphocytosis | — | — | Expected pharmacodynamic effect |
| Fatigue | — | — | Reported |
| Overall tolerability | — | — | Favourable across the approved indications; the compound has a long clinical safety record in the countries where it is authorised |
Compound Evidence Institute · CEI-TR-0119/3 · https://compoundevidence.com/trials/ta1-hbv-1/results/ · retrieved 30 July 2026